Positron tomographic assessment of androgen receptors in prostatic carcinoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 32, Issue 3, 2005, Pages 344-350

  Dehdashti, Farrokh ^a,c   Picus, Joel ^a,b   Michalski, Jeff M ^a,b   Dence, Carmen S ^c   Siegel, Barry A ^a,c   Katzenellenbogen, John A ^d   Welch, Michael J ^a,c  

^a USA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Androgen; Cancer; PET; Prosteate; Receptor

Indexed keywords

16BETA FLUORO 5ALPHA DIHYDROTESTOSTERONE F 18; ANDROGEN RECEPTOR; ANTIANDROGEN; FLUTAMIDE; RADIOPHARMACEUTICAL AGENT; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BIOACCUMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG UPTAKE; FATTY LIVER; HUMAN; LIVER METASTASIS; MALE; POSITRON EMISSION TOMOGRAPHY; PROSTATE BIOPSY; PROSTATE CARCINOMA; QUANTITATIVE ANALYSIS; RADIODIAGNOSIS; SENSITIVITY ANALYSIS; STANDARD; TUMOR BIOPSY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; DIHYDROTESTOSTERONE; FEASIBILITY STUDIES; FLUORINE RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 17644401698     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-1764-5     Document Type: Article

References (24)

1. Huggins C. The effect of castration, of estrogen and of androgen injections on serum phosphatases in metastatic carcinoma of the prostate: studies on prostate cancer. Cancer Res 1941;1:293-7.
2. Buchanan G, Irvine RA, Coetzee GA, Tilley WD. Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev 2001;20:207-23.
3. Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004;22:2927-41.
4. Mintun MA, Welch MJ, Siegel BA, Mathias CJ, Brodack JW, McGuire AH, et al. Breast cancer: PET imaging of estrogen receptors. Radiology 1988;169:45-8.
5. 18F]fluoro- 17β-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991;32:1526-31.
6. 18F]fluoro-16 α-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas. J Nucl Med 1991;32:1532-7.
7. Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonasera TJ, Fusselman MJ, et al. Positron tomographic assessment of estrogen receptors in breast cancer. Comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995;36:1766-74.
8. Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. PET assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 1999;26:51-6.
9. 18F]fluoro-17β-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 1996;2:933-9.
10. Bonasera TA, O'Neil JP, Xu M, Dobkin JA, Cutler PD, Lich LL, et al. Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons. J Nucl Med 1996;37:1009-15.
11. Liu A, Dence CS, Welch MJ, Katzenellenbogen JA. Fluorine-18-labeled androgens: radiochemical synthesis and tissue distribution studies on six fluorine-substituted androgens, potential imaging agents for prostatic cancer. J Nucl Med 1992;33:724-34.
12. Kubota K, Matsuzawa T, Ito M, Ito K, Fujiwara T, Abe Y, et al. Lung tumor imaging by positron emission tomography using C-11 L-methionine. J Nucl Med 1985;26:37-42.
13. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics 2005. CA Cancer J Clin 2005;55:10-30.
14. Thenot S, Charpin M, Bonnet S, Cavailles V. Estrogen receptor cofactors expression in breast and endometrial human cancer cells. Mol Cell Endocrinol 1999;156:85-93.
15. Kozlowski JM, Ellis WJ, Grayhack JT. Advanced prostatic carcinoma. Early versus late endocrine therapy. Urol Clin North Am 1991;18:15-24.
16. Hyytinen ER, Haapala K, Thompson J, Lappalainen I, Roiha M, Rantala I, et al. Pattern of somatic androgen receptor gene mutations in patients with hormone-refractory prostate cancer. Lab Invest 2002;82:1591-8.
17. 2-terminal and steroid-binding domains. J Biol Chem 1993;268:19004-12.
18. Culig Z, Hobisch A, Hittmair A, Peterziel H, Cato AC, Bartsch G, et al. Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate 1998;35:63-70.
19. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and over expression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61:3550-5.
20. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A 1999;96:5458-63.
21. Bentel JM, Tilley WD. Androgen receptors in prostate cancer. J Endocrinol 1996;151:1-11.
22. Sadar MD, Hussain M, Bruchovsky N. Prostate cancer: molecular biology of early progression to androgen independence. Endocr Relat Cancer 1999;6:487-502.
23. Jenster G. The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol 1999;26:407-21.
24. 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 2004;45:366-73.